Psybio Therapeau Stock Price, News & Analysis

PsyBio Therapeutics Corp (PSYBF) is an intellectual property-driven biotechnology company focused on developing novel, bespoke, psycho-targeted therapeutics to enhance mental and neurological health. With recent government approval to manufacture biosynthetic tryptamines, including their lead compound PsyBio-11142, the company is poised to advance to human clinical trials. PsyBio's bio-medicinal chemistry approach involves utilizing psychoactive compounds as templates for developing precursors and analogs, with ongoing research in naturally occurring tryptamines found in hallucinogenic mushrooms and other sources. The company's leadership role in the industry is underscored by its commitment to scientific advancements and therapeutic development.